Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
Tarih
2020Yazar
Cil, I
EKENEL, Meltem
Zirtiloglu, A.
Karabulut, S.
Tural, D.
Aydin, E.
Üst veri
Tüm öğe kaydını gösterÖzet
Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.
Koleksiyonlar
- Makale [92796]